Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy decreases lean body mass and appendicular skeletal muscle mass index even until one year after the final treatment in patients with B-cell non-Hodgkin lymphoma.
Nakao S, Ngayama D, Nakaseko C, Shimizu N. Nakao S, et al. Among authors: shimizu n. J Chemother. 2024 Jul 11:1-7. doi: 10.1080/1120009X.2024.2376454. Online ahead of print. J Chemother. 2024. PMID: 38989820
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma.
Shimizu N, Ngayama D, Watanabe Y, Yamaguchi T, Nakamura S, Ohira M, Saiki A, Onda H, Yamaoka S, Abe K, Nakaseko C, Tatsuno I. Shimizu N, et al. J Chemother. 2022 Jul;34(4):258-263. doi: 10.1080/1120009X.2021.1988202. Epub 2021 Oct 18. J Chemother. 2022. PMID: 34661507
Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy.
Tsukamoto S, Takeuchi M, Kawajiri C, Tanaka S, Nagao Y, Sugita Y, Yamazaki A, Kawaguchi T, Muto T, Sakai S, Takeda Y, Ohwada C, Sakaida E, Shimizu N, Yokote K, Iseki T, Nakaseko C. Tsukamoto S, et al. Among authors: shimizu n. Int J Hematol. 2012 Feb;95(2):204-8. doi: 10.1007/s12185-011-0982-9. Epub 2011 Dec 9. Int J Hematol. 2012. PMID: 22160836
Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma.
Kawaguchi T, Ohwada C, Takeuchi M, Shimizu N, Sakaida E, Takeda Y, Sakai S, Tsukamoto S, Yamazaki A, Sugita Y, Higashi M, Fujikawa K, Matsue K, Yokote K, Tamaru J, Bujo H, Nakaseko C. Kawaguchi T, et al. Among authors: shimizu n. Leuk Lymphoma. 2014 Oct;55(10):2391-4. doi: 10.3109/10428194.2014.880430. Epub 2014 Mar 7. Leuk Lymphoma. 2014. PMID: 24401112 No abstract available.
Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.
Kawajiri C, Tanaka H, Hashimoto S, Takeda Y, Sakai S, Takagi T, Takeuchi M, Ohwada C, Sakaida E, Shimizu N, Nakaseko C. Kawajiri C, et al. Among authors: shimizu n. Int J Hematol. 2014 Apr;99(4):513-8. doi: 10.1007/s12185-014-1531-0. Epub 2014 Feb 15. Int J Hematol. 2014. PMID: 24532437
3,235 results